Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma

Gonzalo Sapisochin; Wei Chen Lee; Dong Jin Joo; Jae-Won Joh; Koichiro Hata; Arvinder Singh Soin; Uday Kiran Veldandi; Shuhei Kaneko; Matthias Meier; Denise Leclair; Gangadhar Sunkara; Long Bin Jeng

doi:10.12659/AOT.937988

22 November 2022 : Original article

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma

Gonzalo Sapisochin

^1ADE*, Wei Chen Lee^2ABCDE, Dong Jin Joo^3ABD, Jae-Won Joh^4ABE, Koichiro Hata

^56BCDE, Arvinder Singh Soin^7ACDE, Uday Kiran Veldandi^8ABCDEF, Shuhei Kaneko^9ACDE, Matthias Meier^10ACDEG, Denise Leclair^11DE, Gangadhar Sunkara^11CDEF, Long Bin Jeng^12AB

DOI: 10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Kaplan-Meier plot for proportion of patients (ITT population) free from HCC recurrence (A) and free from HCC recurrence or death (B). EVR+rTAC – everolimus plus reduced tacrolimus; HCC – hepatocellular carcinoma; ITT – intent-to-treat; sTAC – standard tacrolimus. Created using SAS version 9.4.

Back to the Article

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma

Your Privacy